Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Alvotech Inks Long-Term Agreement With A Strategic Partner To Further Enhance Access To Adalimumab-ryvk In US Market

Author: Benzinga Newsdesk | April 19, 2024 06:11am

"This new partnership agreement supports our financial guidance and reflects Alvotech's strong commitment to increasing patient access to more affordable healthcare," said Robert Wessman, Chairman and CEO of Alvotech.

The current multi-product commercialization partnership between Teva Pharmaceuticals and Alvotech remains unchanged and Teva will continue to commercialize adalimumab-ryvk under the SIMLANDI® brand in the U.S.

Posted In: ALVO TEVA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist